MASH may require personalized treatment as distinct disease subtypes emerge
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting an estimated 38% of adults worldwide. Its progressive form, MASH, is characterized by inflammation and damage to liver cells and can lead to liver cirrhosis and liver cancer, among ot
<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting an estimated 38% of adults worldwide. Its progressive form, MASH, is characterized by inflammation and damage to liver cells and can lead to liver cirrhosis and liver cancer, among ot</p>